Editor's Letter

Published on 15 June 2015

What to look forward to in GaBI Journal, 2015, Issue 2

This entire issue of the GaBI Journal could be titled ‘World News’ since it contains manuscripts describing global generics and biosimilar activities. The Commentary by Leng et al. describes regulatory events in South Africa that led to claims of delay in marketing approval of generic drug products. The authors discuss the relationship between regulatory policies…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0402.013

Editor's Letter

Published on 14 August 2019

Unmet potential of Generics and Biosimilars to reduce healthcare costs

The high cost of pharmaceuticals has been gaining increasing attention as a threat to both healthcare systems and patients’ access to care globally. This GaBI issue contains articles focusing on the fact that generics and follow-on biologicals have yet to achieve their potential to mitigate these costs in most if not all countries. In an…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2019.0802.006

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2016. Dr Ali M Alhomaidan, Saudi Arabia Dr Srinivas Chollangi, USA Professor Joshua Cohen, USA Professor Daan J Crommelin, The Netherlands Professor Theodor…

Contents Editor's Letter What to look forward to in GaBI Journal, 2013, Issue 2 Editorial National and regional activities by sickness funds in Austria to encourage the rational use of medicines Letters to the Editor Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx Challenges to generic medicines utilization in Yemeni healthcare system Original Research…

Pro-generics policies and the backlog in medicines registration in South Africa: implications for access to essential and affordable medicines Comment by Ernest Schay, Bayer Thank you for this very interesting article. From a veterinary medicine perspective, it would certainly explain why such medicines are also experiencing a delay, as veterinary medicines use the same P & A (Pharmaceutical…

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2015.0404.044

Author byline as per print journal: Chad Rieger1, MBA; Lisa Hall1, PhD; David Lim2,3, DPH Abstract: Bandiera et al. (2002) identified the potential for competitors’ promotional materials to use certain terms with technical meanings, such as ‘interchangeable’ and ‘substitution’, in a misleading way in Australia. Submitted: 30 June 2022; Revised: 4 July 2022; Accepted: 5…

Australia, interchangeability, substitution

DOI: 10.5639/gabij.2022.1102.009

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s third volume Editorial Availability and procurement of generics in hospitals among medium-sized European countries Letters to the Editor Access to alternative biopharmaceuticals in low- and middle- income countries Commentary Biosimilars versus ‘biobetters’ — a regulator’s perspective Original Research Availability and procurement conditions of originator and…

Abstract: A study of the factors influencing generics makers’ decision on whether to enter a specific market found that firm size, market revenue and expected competition all had an effect. Market size was also positively associated with the entry of more generics. The effect of a financial subsidy on generics entry was also investigated. Submitted:…

Author(s): GaBI Journal Editor

financial subsidy, generics entry, generics market, price competition

DOI: 10.5639/gabij.2016.0503.037

Editor's Letter

Published on 29 September 2021

Latest features in GaBI Journal, 2021, Issue 3

This issue of GaBI Journal contains articles dealing with some very practical issues related to the evaluation, describing, and use of generic and biosimilar products. These issues include the uncertainty associated with extrapolating results of studies that used small, non-representative study populations, study sites, or product types. These problems are evident in the evaluation of…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2021.1003.012

Contents Editor's Letter Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal Letters to the Editor The ethics of biosimilars Austria increases dialogue in order to involve physicians more with biosimilars Editorial Health authority perspective on biosimilars Commentary The case for biosimilars–a payer’s perspective Original…

Healthcare professionals working with HIV patients in high-income countries are likely to accept the introduction of generic antiretroviral drugs (ARVs), according to a study carried out by researchers in Ireland [1]. Between the end of August and November 2015, 30 healthcare professionals completed an online survey about the introduction of generic ARVs. Descriptive and univariate…

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0603.029

Editor's Letter

Published on 11 December 2015

Fourth and final issue of GaBI Journal’s fourth volume

This last issue of 2015 starts with a Commentary by Drs Christoph Baumgärtel and Brian Godman concerning the approval of generic versions of narrow therapeutic margin products; including immunosuppressant drugs. The authors explain why they find concerns that have been raised by some clinicians concerning the bioavailability margins needed for approval of narrow therapeutic drugs…

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2015.0404.034